Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on MOLN stock, giving a Buy rating on August 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang has given his Buy rating due to a combination of factors that highlight Molecular Partners’ promising pipeline and financial stability. The company has reported a slight delay in the IND submission for its lead program, MP0712, now expected in the third quarter of 2025. Despite this, the initiation of the Phase I study and the release of initial clinical data are still on track for 2025 and the first half of 2026, respectively. The anticipated human imaging data from the collaboration with NuMeRI in South Africa, expected in the fourth quarter of 2025, is seen as a potential catalyst for the stock.
Additionally, Molecular Partners has a strong financial position, ending the second quarter of 2025 with CHF 114.5 million in cash and equivalents, providing a cash runway into 2028. This financial stability, along with the strategic appointment of Martin Steegmaier as Chief Scientific Officer, supports the company’s ongoing development efforts. The focus on MP0712, a promising candidate in the radiopharmaceutical space, and the reliable supply of radioisotopes through its partnership with Orano Med, further reinforce the positive outlook. These elements combined justify the Buy rating on Molecular Partners’ stock.
In another report released on August 25, LifeSci Capital also maintained a Buy rating on the stock with a $12.00 price target.